MCID: SYS052
MIFTS: 16

Systemic Lupus Erythematosus 13

Categories: Genetic diseases, Rare diseases, Nephrological diseases, Immune diseases, Bone diseases, Skin diseases

Aliases & Classifications for Systemic Lupus Erythematosus 13

MalaCards integrated aliases for Systemic Lupus Erythematosus 13:

Name: Systemic Lupus Erythematosus 13 54
Systemic Lupus Erythematosus, Susceptibility to, 13 13

Classifications:



External Ids:

OMIM 54 612378

Summaries for Systemic Lupus Erythematosus 13

MalaCards based summary : Systemic Lupus Erythematosus 13, is also known as systemic lupus erythematosus, susceptibility to, 13. An important gene associated with Systemic Lupus Erythematosus 13 is SLEB13 (Systemic Lupus Erythematosus, Susceptibility To, 13). The drugs belimumab and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include liver and heart.

Description from OMIM: 612378

Symptoms & Phenotypes for Systemic Lupus Erythematosus 13

Clinical features from OMIM:

612378

Drugs & Therapeutics for Systemic Lupus Erythematosus 13

Drugs for Systemic Lupus Erythematosus 13 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 45)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
belimumab Approved Phase 3 356547-88-1 5957 10451420
2
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
3
Abatacept Approved Phase 2, Phase 3 332348-12-6 10237
4
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
5
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
6
Mycophenolate mofetil Approved, Investigational Phase 2, Phase 3 128794-94-5 5281078
7
Mycophenolic acid Approved Phase 2, Phase 3 24280-93-1 446541
8
Prednisone Approved, Vet_approved Phase 2, Phase 3 53-03-2 5865
9 Antibodies Phase 3,Phase 1,Phase 2
10 Immunoglobulins Phase 3,Phase 1,Phase 2
11 Anti-Inflammatory Agents Phase 3,Phase 2
12 Anti-Inflammatory Agents, Non-Steroidal Phase 3
13 Antimalarials Phase 3
14 Immunosuppressive Agents Phase 3,Phase 2
15 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
16 Pharmaceutical Solutions Phase 2, Phase 3,Phase 1
17 Antirheumatic Agents Phase 2, Phase 3
18 Methylprednisolone acetate Phase 2, Phase 3
19 Methylprednisolone Hemisuccinate Phase 2, Phase 3
20 Prednisolone acetate Phase 2, Phase 3
21 Prednisolone hemisuccinate Phase 2, Phase 3
22 Prednisolone phosphate Phase 2, Phase 3
23 Anti-Bacterial Agents Phase 2, Phase 3
24 Antibiotics, Antitubercular Phase 2, Phase 3
25 Antineoplastic Agents, Hormonal Phase 2, Phase 3
26 glucocorticoids Phase 2, Phase 3
27 Hormone Antagonists Phase 2, Phase 3
28 Hormones Phase 2, Phase 3
29 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
30
Acetylcysteine Approved, Investigational Phase 1, Phase 2 616-91-1 12035
31
Bilirubin Phase 1, Phase 2 635-65-4 5280352
32 Liver Extracts Phase 1, Phase 2
33 Interferon-alpha Phase 2
34 interferons Phase 2
35 Respiratory System Agents Phase 1, Phase 2
36 Antidotes Phase 1, Phase 2
37 Anti-Infective Agents Phase 1, Phase 2
38 Antioxidants Phase 1, Phase 2
39 Antiviral Agents Phase 1, Phase 2
40 Expectorants Phase 1, Phase 2
41 N-monoacetylcystine Phase 1, Phase 2
42 Protective Agents Phase 1, Phase 2
43
Omalizumab Approved, Investigational Phase 1 242138-07-4
44 Anti-Allergic Agents Phase 1
45 Anti-Asthmatic Agents Phase 1

Interventional clinical trials:

(show all 24)

id Name Status NCT ID Phase Drugs
1 A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT01484496 Phase 3 Standard therapy
2 Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus Active, not recruiting NCT02446899 Phase 3 Placebo
3 A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus Active, not recruiting NCT02504645 Phase 3 IPP-201101;Placebo
4 Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus Active, not recruiting NCT02446912 Phase 3 Placebo
5 Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis Terminated NCT00430677 Phase 2, Phase 3 Corticosteroids (prednisone or prednisolone);Abatacept;Abatacept;Mycophenolate mofetil (MMF);Abatacept
6 Umbilical Cord Mesenchymal Stem Cells for Patients With Primary Biliary Cirrhosis Unknown status NCT01662973 Phase 1, Phase 2
7 Umbilical Cord Mesenchymal Stem Cells for Patients With Autoimmune Hepatitis Unknown status NCT01661842 Phase 1, Phase 2
8 Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects Completed NCT01534403 Phase 2
9 A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus Completed NCT01283139 Phase 2
10 A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus Completed NCT00657189 Phase 2 MEDI-545;MEDI-545;MEDI-545;MEDI-545;Placebo
11 A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE) Recruiting NCT02660944 Phase 2 RSLV-132;Placebo
12 Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches Recruiting NCT02270957 Phase 2
13 Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus Active, not recruiting NCT02265744 Phase 2 BMS-931699;Placebo matching BMS-931699
14 Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine Suspended NCT00775476 Phase 1, Phase 2 N-acetylcysteine;N-acetylcysteine;Placebo
15 An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184 Terminated NCT01777256 Phase 2 GSK2586184 50 mg;GSK2586184 100 mg;GSK2586184 200 mg;GSK2586184 400 mg;Placebo
16 A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE) Completed NCT01686555 Phase 1 ABT-199
17 Omalizumab for Lupus Completed NCT01716312 Phase 1 Omalizumab
18 Multiple Ascending Dose Study To Assess The Safety Profile Of SAR113244 Versus Placebo In Lupus Male And Female Patients Completed NCT02321709 Phase 1 SAR113244;placebo
19 A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK2586184 and the Effect of Food and Gender Completed NCT01687309 Phase 1 GSK2586184 800mg single and repeat dose;Placebo-to-match GSK2586184
20 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 in Healthy Volunteers and Participants With Systemic Lupus Erythematosus Completed NCT02106897 Phase 1 BIIB059;Placebo
21 Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis Completed NCT00818948 Phase 1 AMG 811
22 Pharmacodynamics Assessment Study After Single Subcutaneous Dose Of SAR113244 Versus Placebo In Lupus Male And Female Patients Withdrawn NCT02331810 Phase 1 SAR113244;placebo
23 HIPP Learning to Live Better With Lupus: The Health Improvement and Prevention Program in Systemic Lupus Erythematosus Unknown status NCT00188357
24 Prospective Maternal Surveillance of SSA (Sjögren Syndrome A) Positive Pregnancies Using a Hand-held Fetal Heart Rate Monitor Recruiting NCT02920346

Search NIH Clinical Center for Systemic Lupus Erythematosus 13

Genetic Tests for Systemic Lupus Erythematosus 13

Anatomical Context for Systemic Lupus Erythematosus 13

MalaCards organs/tissues related to Systemic Lupus Erythematosus 13:

39
Liver, Heart

Publications for Systemic Lupus Erythematosus 13

Variations for Systemic Lupus Erythematosus 13

Expression for Systemic Lupus Erythematosus 13

Search GEO for disease gene expression data for Systemic Lupus Erythematosus 13.

Pathways for Systemic Lupus Erythematosus 13

GO Terms for Systemic Lupus Erythematosus 13

Sources for Systemic Lupus Erythematosus 13

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....